Prevention, Diagnosis & Treatment

Bayer’s U.S. oncology expertise is deep and wide. In the U.S., Bayer currently markets treatments for prostate, colorectal, follicular lymphoma, kidney, liver, and thyroid cancers as well as a precision treatment for NTRK fusions, which are found in more than 25 solid tumor types, including pediatric cancers. Bayer oncology seeks to address gaps in treatment by developing new therapeutic options that improve patient benefit and their corresponding health outcomes.

A global leader in the cardiovascular (CV) space, Bayer upholds a long-standing commitment to delivering science for a better life by advancing innovative treatments. 

Bayer’s U.S. Cardiovascular and Renal Franchise, which began with the discovery and development of a number of vital therapies, now includes several products and compounds in various stages of preclinical and clinical development with the potential to impact the way that CV and kidney diseases are treated. 

Alongside partners, advocates, patients, and clinical teams, Bayer is focused on advancing new treatment approaches for areas of high unmet medical need in CV and kidney disease.
 

In the area of Pulmonary Hypertension, scientists at Bayer discovered direct stimulators of soluble guanylate cyclase stimulators (sGC), a new way to widen the blood vessels, to lower blood pressure in the lungs and relieve the heart. Bayer’s compound became the first member of this distinct class of medicines and the first drug therapy to be approved in two forms of pulmonary hypertension. Its distinct mode of action has the potential to overcome a number of limitations of previously approved treatments for pulmonary arterial hypertension (PAH) and it is the first drug therapy to become available for another type of PH, inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent or recurrent CTEPH after surgical treatment.

Bayer has been an advocate and leader in women’s healthcare for more than 60 years, introducing the first oral contraception in 1968 and now leading the IUD (intrauterine device) contraceptive market in the US. With the expansion into menopause management, Bayer is committed to finding solutions throughout the life course for women and is continually looking at opportunities to fulfill the unmet needs for various gynecological diseases and conditions that would provide more options to women now and in the future.

Bayer has numerous compounds for hemophilia A currently on the market and continues to invest in the development of innovative treatments and solutions for people with hemophilia across the world. This focus on advancing hemophilia care and treatment show our commitment to the community.

Being diagnosed through radiology is often the first step in a patient’s journey. These helpful diagnostic tools give healthcare professionals control to properly identify an ailment and know if treatment is working. Bayer provides radiologists with a portfolio of diagnostic imaging products and services along the radiology workflow and engages collaboratively with original equipment manufacturers (OEMs) of diagnostic imaging scanners and healthcare IT partners.

Bayer has been committed to radiology for more than 100 years and continues to partner with radiologists to guide diagnostic care. Explore our radiology solutions.